drugset / Trial / NCT03969706
Abemaciclib in Patients with Oligodendroglioma
Phase 2
Active not recruiting
10 enrolled
Stephen Bagley, MD, MSCE
Abramson Cancer Center at Penn Medicine · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
Timeline
- Start
- 2019-05-15
- Primary completion
- 2025-05-15
- Completion
- 2027-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |